New insider activity at LivaNova ( (LIVN) ) has taken place on November 19, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Director Brooke Story recently sold 250 shares of LivaNova stock, amounting to a total transaction value of $13,485.
Recent Updates on LIVN stock
LivaNova’s stock has seen positive developments following its recent Investor Day, where the company outlined its strategic growth plans and long-range financial targets. Analysts from Mizuho and Baird have raised their price targets for LivaNova, citing the company’s comprehensive roadmap to accelerate growth through 2028 and beyond. This includes maximizing core businesses, scaling its Obstructive Sleep Apnea (OSA) segment, and leveraging its leadership in the Cardiopulmonary and Epilepsy markets. The company’s strategic initiatives, such as the commercialization of its OSA device and advancements in its Epilepsy treatment offerings, are expected to drive significant revenue growth and margin expansion. Additionally, LivaNova’s strong Q3 performance and promising growth prospects have reinforced its favorable outlook among analysts.
Spark’s Take on LIVN Stock
According to Spark, TipRanks’ AI Analyst, LIVN is a Neutral.
LivaNova’s overall score is driven by strong earnings call performance and positive technical indicators. However, profitability challenges and valuation concerns weigh on the score. The company’s ability to address supply constraints and currency impacts will be crucial for future performance.
To see Spark’s full report on LIVN stock, click here.
More about LivaNova
YTD Price Performance: 15.52%
Average Trading Volume: 561,568
Technical Sentiment Signal: Buy
Current Market Cap: $2.93B